Antioxidant targeting by deferiprone in diseases related to oxidative damage . Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ.; Front Biosci (Landmark Ed). 2014 Jun 1;19:862-885. http://dx.doi.org/10.2741/4253
Keywords:antioxidant pharmaceuticals, free radical damage (FRD), Deferiprone (L1), iron overload, cardiomyopathy, acute kidney disease, Friedreich ataxia.